New data reveal that while most women with postpartum depression start antidepressant treatment, many discontinue treatment early—highlighting persistent gaps in postpartum care.
An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
AI and machine learning models, using tools like the EPDS and data from the electronic health record, may help clinicians detect and even prevent postpartum depression.
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
Early identification and treatment of maternal sleep problems during pregnancy may lower the risk for postpartum depression and improve both maternal and infant sleep outcomes.
We are pleased to share that our More Than Blue documentary is now screening across the globe through our new partnership with ROCO films.
Behavioral activation intervention, whether delivered by specialists or non-specialists, was effective for the treatment of perinatal depression and anxiety.
Behavioral activation significantly reduced suicidal ideation in women with perinatal depression, showing effectiveness whether delivered in-person or remotely by specialists and non-specialists.
Treatment with zuranolone, a novel oral antidepressant for postpartum depression, raises important questions for breastfeeding individuals. While recent studies show minimal transfer into breast milk, we do not yet have enough information to recommend breastfeeding while taking zuranolone.
New documentary illuminates the faces and voices of postpartum depression across America.
